Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer

Figure 6

Expressions of Arg-1, NF-κB p65, p-NF-κB p65, MAPK, p-MAPK, and AKT in subcutaneous tumors from mice treated with radioimmunotherapy or triple therapy. RT: radiotherapy; IO: immunotherapy; AN: anlotinib.